Arrowhead Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDArrowhead Pharmaceuticals, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 94), indicating clear outperformance against the broad market. Earnings contraction of 134% provides fundamental context to the price action. However, price is extended 20% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $71.88 | +8.45% | ABOVE |
| 50 SMA | $64.87 | +20.16% | ABOVE |
| 100 SMA | $65.61 | +18.81% | ABOVE |
| 150 SMA | $58.52 | +33.21% | ABOVE |
| 200 SMA | $49.80 | +56.54% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ARWR in an uptrend right now?
ARWR has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ARWR overbought or oversold?
ARWR's RSI (14) is 70. The stock is in neutral territory, neither overbought nor oversold.
Is ARWR outperforming the market?
ARWR has a Relative Strength (RS) Rating of 94 out of 99. Yes, ARWR is a market leader, outperforming 94% of all stocks over the past 12 months.
Where is ARWR in its 52-week range?
ARWR is trading at $77.95, which is 98% of its 52-week high ($79.48) and 98% above its 52-week low ($12.44).
How volatile is ARWR?
ARWR has a Beta of 1.81 and 52-week volatility of 65%. It's more volatile than the S&P 500 - expect bigger swings.